|1.||Aoki, Takumi: 1 article (07/2013)|
|2.||Mochizuki, Hidenori: 1 article (07/2013)|
|3.||Asaoka, Yoshiji: 1 article (07/2013)|
|4.||Kaino, Mie: 1 article (07/2013)|
|5.||Yoshizawa, Yoshitaka: 1 article (07/2013)|
|6.||Yamada, Masateru: 1 article (07/2013)|
|7.||Noda, Hidetoshi: 1 article (07/2013)|
|8.||Shimozono, Rieko: 1 article (07/2013)|
10/01/1990 - "These two 1,4-dihydropyridines, NK-250 and NK-252, are unique compounds because they were effective not only in circumventing the drug resistance, but also in potentiating the action of antitumor drugs against drug-sensitive tumors."
10/01/1990 - "We investigated whether two representative 1,4-dihydropyridine derivatives, NK-250 and NK-252, could potentiate the antitumor activity of multiple anticancer agents including vincristine (VCR), vinblastine, vindesine and actinomycin D in drug-resistant tumor cells and their parental drug-sensitive tumor cells. "
10/01/1990 - "In chemotherapeutic experiments with leukemia-bearing mice, NK-250 or NK-252 was orally administered in combination with different drugs of the MDR phenotype administered intraperitoneally. "
10/01/1990 - "NK-250 and NK-252 at 5-10 microM almost completely reversed VCR resistance in cultured VCR-resistant P388/VCR cells derived from the mouse drug-sensitive P388/S leukemia cell line and also potentiated the cytocidal activity of VCR in drug-sensitive P388/S cells. "
|3.||Vinblastine (Vinblastine Sulfate)
|5.||Antineoplastic Agents (Antineoplastics)